CervoMed Inc.
CRVOHealthcare|Biotechnology|US
$1.42
-0.03 (-2.07%)
DCF Value
$0.80
Tangible Book / Share
$1.15
Cash / Share
$1.30
Financials
Financial Snapshot
Market Cap
$21.5M
Enterprise Value
$15.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$28.5M
Cash & Investments
$19.6M
Net Cash
$19.6M
Free Cash Flow (TTM)
-$26.6M
Operating CF (TTM)
-$26.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$19.6M
Quarterly Burn
$6.6M
Monthly Burn
$2.2M
Est. Runway
~2.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.6M | $8.9M | $8.0M | $14.2M | $18.5M | $37.3M | $4.1M | $7.8M | $38.9M | $20.9M | $19.6M | |
| Operating Cash Flow | -$10.8M | -$12.3M | -$10.8M | -$9.9M | -$13.6M | -$14.5M | -$2.6M | -$7.4M | -$16.5M | -$23.4M | -$26.6M | |
| Free Cash Flow | -$10.8M | -$12.8M | -$10.8M | -$9.9M | -$13.6M | -$14.5M | -$2.6M | -$7.4M | -$16.5M | -$23.4M | -$26.6M | |
| Capital Expenditure | -$2.3K | -$447.8K | $0.00 | $0.00 | $0.00 | $0.00 | -$1.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $1.8M | $20.1M | $9.9M | $16.0M | $17.9M | $33.3M | $0.00 | $11.1M | $46.4M | $4.6M | $18.6M |
R&D Spending
R&D (TTM)
$19.0M
R&D Intensity
—
R&D Growth vs Prior
-13.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $6.3M | $5.1M | $5.8M | $6.6M | $9.4M | $8.5M | $1.3M | $8.4M | $18.8M | $21.8M | $19.0M | |
| SG&A | $8.6M | $6.2M | $6.2M | $4.8M | $6.4M | $7.4M | $2.1M | $6.5M | $9.2M | $10.5M | $10.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $25.3K | $68.0K | $110.4K | $97.9K | $103.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$25.3K | -$68.0K | -$110.0K | -$97.9K | -$103.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $6.3M | $5.1M | $5.8M | $6.6M | $9.4M | $8.5M | $1.3M | $8.4M | $18.8M | $21.8M | $19.0M | |
| SG&A | $8.6M | $6.2M | $6.2M | $4.8M | $6.4M | $7.4M | $2.1M | $6.5M | $9.2M | $10.5M | $10.3M | |
| Operating Income | -$14.9M | -$11.3M | -$12.0M | -$11.6M | -$16.0M | -$24.7M | -$3.5M | -$7.8M | -$18.2M | -$28.3M | -$29.2M | |
| Interest Expense | $29.7K | $2.9M | $0.00 | $0.00 | $0.00 | $0.00 | $587.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$18.4M | -$2.4M | -$18.8M | -$11.5M | -$15.9M | -$24.5M | -$5.8M | -$2.2M | -$16.3M | -$27.0M | -$28.5M | |
| Net Income | -$18.0M | -$1.4M | -$18.4M | -$11.8M | -$14.2M | -$24.1M | -$5.8M | -$2.2M | -$16.3M | -$27.0M | -$28.5M | |
| EPS (Diluted) | -1982.96 | -120.35 | -424.93 | -131.95 | -22.50 | -18.51 | -11.20 | -0.82 | -2.02 | -2.98 | -2.76 | |
| EBITDA | -$18.3M | $566.0K | -$18.7M | -$11.4M | -$15.8M | -$15.9M | -$5.8M | -$2.2M | -$16.3M | -$27.0M | -$28.7M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.04 | 0.09 | 0.72 | 1.30 | 0.52 | 2.66 | 8.07 | 9.04 | 15.12 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $8.9M | $8.0M | $14.2M | $18.5M | $37.3M | $4.1M | $7.8M | $9.0M | $8.2M | $6.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $29.9M | $12.6M | $13.5M | |
| Total Current Assets | $1.6M | $9.7M | $8.9M | $14.6M | $18.8M | $37.8M | $4.2M | $10.0M | $43.1M | $22.6M | $21.3M | |
| Total Assets | $17.5M | $26.1M | $18.2M | $24.3M | $27.7M | $37.8M | $4.2M | $10.0M | $43.1M | $23.4M | $21.3M | |
| Total Current Liabilities | $4.4M | $2.7M | $804.0K | $1.7M | $2.4M | $2.9M | $13.2M | $2.6M | $3.9M | $4.7M | $4.0M | |
| Long-Term Debt | $550.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.3M | $4.9M | $2.6M | $4.1M | $2.9M | $2.9M | $13.2M | $2.6M | $3.9M | $5.2M | $4.0M | |
| Stockholders' Equity | $9.2M | $21.2M | $15.6M | $20.1M | $24.8M | $34.9M | -$9.0M | $7.4M | $39.2M | $18.2M | $17.4M | |
| Retained Earnings | -$60.2M | -$61.6M | -$79.9M | -$91.7M | -$105.9M | -$130.0M | -$52.3M | -$54.4M | -$70.7M | -$97.7M | -$118.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.8M | -$12.3M | -$10.8M | -$9.9M | -$13.6M | -$14.5M | -$2.6M | -$7.4M | -$16.5M | -$23.4M | -$26.6M | |
| Capital Expenditure | -$2.3K | -$447.8K | $0.00 | $0.00 | $0.00 | $0.00 | -$1.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$10.8M | -$12.8M | -$10.8M | -$9.9M | -$13.6M | -$14.5M | -$2.6M | -$7.4M | -$16.5M | -$23.4M | -$26.6M | |
| Investing Cash Flow | $8.5M | -$447.8K | $0.00 | $0.00 | $0.00 | $4.0K | $0.00 | $0.00 | -$28.7M | $18.1M | $4.6M | |
| Financing Cash Flow | $1.8M | $20.1M | $9.9M | $16.0M | $17.9M | $33.3M | $0.00 | $11.1M | $46.4M | $4.6M | $18.6M | |
| Issuance of Stock | -$54.3K | $22.0M | $10.8M | $12.3M | $10.8M | $31.1M | $0.00 | $810.0K | $46.4M | $4.6M | $9.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.9M | -$1.9M | -$550.0K | $0.00 | $0.00 | $6.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $736.1K | $897.3K | $333.8K | $407.6K | $1.4M | $1.4M | $1.0M | |
| Net Change in Cash | -$444.3K | $7.3M | -$905.3K | $6.2M | $4.3M | $18.8M | -$33.2M | $3.7M | $1.2M | -$764.0K | -$3.4M |
Dilution Tracker
Shares outstanding grew 1159.7% over 5 years — significant dilution
Shares Outstanding
15M
5-Year Share Growth
+1159.7%
Stock Issuance (TTM)
$9.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.04 | 0.09 | 0.72 | 1.30 | 0.52 | 2.66 | 8.07 | 9.04 | 15.12 | |
| Change vs Prior % | — | 24.7% | 281.3% | 106.8% | 702.7% | 81.4% | -60.2% | 413.6% | 203.4% | 12.0% | 67.2% | |
| Stock Issuance | -$54.3K | $22.0M | $10.8M | $12.3M | $10.8M | $31.1M | $0.00 | $810.0K | $46.4M | $4.6M | $9.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $736.1K | $897.3K | $333.8K | $407.6K | $1.4M | $1.4M | $1.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -196.4% | -6.4% | -117.7% | -58.6% | -57.2% | -69.0% | 64.5% | -29.4% | -41.6% | -148.0% | -165.0% | |
| ROA % | -103.2% | -5.2% | -100.9% | -48.6% | -51.2% | -63.7% | -139.6% | -21.8% | -37.8% | -115.2% | -133.7% | |
| ROIC % | -97.7% | -26.6% | -67.5% | -51.0% | -56.2% | -69.4% | -101.7% | -105.9% | -46.5% | -151.0% | -168.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -206.5% | -168.3% | -61.8% | 11.0% | -5.4% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -132.2% | 23.7% | -6.0% | 4.0% | -38.3% | -54.5% | 85.9% | -124.8% | -133.3% | -55.2% | |
| Net Income | -168.4% | 92.4% | -1245.8% | 35.8% | -20.2% | -69.9% | 75.9% | 62.6% | -650.1% | -65.5% | |
| EPS (Diluted) | 93.1% | 93.9% | -253.1% | 68.9% | 82.9% | 17.7% | 39.5% | 92.7% | -146.3% | -47.5% | |
| Operating Cash Flow | -107.7% | -14.5% | 12.6% | 8.5% | -37.5% | -7.0% | 82.3% | -189.6% | -121.9% | -41.9% | |
| Free Cash Flow | -106.1% | -18.7% | 15.7% | 8.5% | -37.5% | -7.0% | 82.3% | -189.6% | -121.9% | -41.9% | |
| R&D Expense | 61.3% | -18.6% | 13.0% | 15.1% | 42.4% | -9.8% | -84.3% | 531.4% | 122.8% | 16.1% | |
| SG&A Expense | 240.8% | -27.9% | -0.4% | -21.6% | 33.3% | 15.5% | -71.3% | 204.8% | 40.6% | 14.4% | |
| Total Assets | 668.0% | 49.5% | -30.4% | 33.4% | 14.2% | 36.5% | -89.0% | 139.9% | 332.0% | -45.7% | |
| Book Value / Share | 665.3% | 90.0% | -81.2% | -37.6% | -84.6% | -22.4% | -164.8% | 116.0% | 75.2% | -58.5% | |
| Debt | 95.4% | -77.4% | -100.0% | 0.0% | -39.6% | -100.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 3803.4% | 24.7% | 281.3% | 106.8% | 702.7% | 81.4% | -60.2% | 413.6% | 203.4% | 12.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.24
10Y Low / Med / High0.15 / 0.87 / 3.92
EV/EBITDAAt Loss
10Y Low / Med / High0.08 / 0.95 / 11.20
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.80
Tangible Book / Share
$1.15
Net Current Assets / Share
$1.15
Graham Net-Net
$1.03
Cash / Share
$1.30
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.28 | -10.76 | -0.35 | -0.26 | -2.67 | -1.26 | -0.68 | -9.30 | -1.16 | -2.65 | -0.51 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 2.52 | 0.69 | 0.41 | 0.15 | 1.74 | 0.87 | -0.44 | 2.75 | 0.48 | 3.92 | 1.24 | |
| EV/EBITDA | -1.31 | 11.20 | 0.08 | 0.95 | -1.57 | 0.44 | -2.11 | -5.76 | -0.61 | -2.34 | -0.54 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-7.98
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $133.3K | $1.0M | $1.3M |
| Net Income | -$17.9M | -$12.2M | -$10.8M |
| EPS | $-2.15 | $-1.48 | $-1.10 |
| # Analysts (EPS) | 5 | 4 | 3 |